Tara Arvedson


Chief Scientific Officer at Hexagon Bio

Tara Averdson

Tara Arvedson is the Chief Scientific Officer at Hexagon Bio. Before joining Hexagon, Tara was an Executive Director of Research at Amgen, where she led small-molecule and large-molecule programs in Oncology, Immuno-Oncology, Inflammation, and Hematology. Notable accomplishments include starting Amgen’s KRAS G12C-targeting effort, which resulted in the first approved KRAS targeting molecule LUMAKRASTM, and leadership of Amgen’s Oncology Bispecific T-cell Engager Platform, which resulted in several clinical candidates.

Tara received her Ph.D. in Biochemistry from the California Institute of Technology and was a Damon Runyon Postdoctoral Fellow at the University of California, San Diego.